60 related articles for article (PubMed ID: 28432000)
1. Determination of thiol-to-protein ratio and drug-to-antibody ratio by in-line size exclusion chromatography with post-column reaction.
Furuki K; Toyo'oka T
Anal Biochem; 2017 Jun; 527():33-44. PubMed ID: 28432000
[TBL] [Abstract][Full Text] [Related]
2. A native SEC-MS workflow and validation for analyzing drug-to-antibody ratio and drug load distribution in cysteine-linked antibody-drug conjugates.
Wu G; Yu C; Yin S; Du J; Zhang Y; Fu Z; Wang L; Wang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124167. PubMed ID: 38823148
[TBL] [Abstract][Full Text] [Related]
3. Determination of thiols and disulfides via HPLC quantification of 5-thio-2-nitrobenzoic acid.
Chen W; Zhao Y; Seefeldt T; Guan X
J Pharm Biomed Anal; 2008 Dec; 48(5):1375-80. PubMed ID: 18926658
[TBL] [Abstract][Full Text] [Related]
4. Physical origin of the peak tailing of monoclonal antibodies in size-exclusion chromatography using bio-compatible systems and columns.
Gritti F; Meyyappan S
Anal Bioanal Chem; 2024 Feb; 416(5):1281-1291. PubMed ID: 38236392
[TBL] [Abstract][Full Text] [Related]
5. Ellman's reagent in promoting crystallization and structure determination of Anabaena CcbP.
Fan XX; Zhou YF; Liu X; Li LF; Su XD
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Nov; 68(Pt 11):1409-14. PubMed ID: 23143261
[TBL] [Abstract][Full Text] [Related]
6. Analytical Quality by Design as applied to the development of a SEC-HPLC platform procedure for the determination of monoclonal antibody purity without mobile phase additives.
Cernosek T; Dalphin M; Jain N; Richter N; Beard S; Wang J; Osborne J; Stone T; Mellal M; Behrens S; Wunderli P
J Pharm Biomed Anal; 2024 Aug; 246():116220. PubMed ID: 38795426
[TBL] [Abstract][Full Text] [Related]
7. Column-free optical deconvolution of intrinsic fluorescence for a monoclonal antibody and its product-related impurities.
Uçan D; Hales JE; Aoudjane S; Todd N; Dalby PA
J Chromatogr A; 2023 Nov; 1711():464463. PubMed ID: 37866332
[TBL] [Abstract][Full Text] [Related]
8. Size exclusion chromatography as green support for forced degradation study of adalimumab.
Kovačić J; Klarić DA; Turk N; Mornar A
Acta Pharm; 2023 Dec; 73(4):709-721. PubMed ID: 38147477
[TBL] [Abstract][Full Text] [Related]
9. Silicon-Containing Thiol-Specific Bioconjugating Reagent.
Zhang Z; Li L; Xu H; Lee CK; Jia Z; Loh TP
J Am Chem Soc; 2024 Jan; 146(3):1776-1782. PubMed ID: 38198597
[TBL] [Abstract][Full Text] [Related]
10. Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.
Tumey LN; Li F; Rago B; Han X; Loganzo F; Musto S; Graziani EI; Puthenveetil S; Casavant J; Marquette K; Clark T; Bikker J; Bennett EM; Barletta F; Piche-Nicholas N; Tam A; O'Donnell CJ; Gerber HP; Tchistiakova L
AAPS J; 2017 Jul; 19(4):1123-1135. PubMed ID: 28439809
[TBL] [Abstract][Full Text] [Related]
11. Development of a facile antibody-drug conjugate platform for increased stability and homogeneity.
Gupta N; Kancharla J; Kaushik S; Ansari A; Hossain S; Goyal R; Pandey M; Sivaccumar J; Hussain S; Sarkar A; Sengupta A; Mandal SK; Roy M; Sengupta S
Chem Sci; 2017 Mar; 8(3):2387-2395. PubMed ID: 28451344
[TBL] [Abstract][Full Text] [Related]
12. [The Characterization of Drug-to-Antibody Ratio and Isoforms of ADCs Using LC and MS Technologies].
Iizuka R; Kotch F; Xu A; Porter T; Shion H; Birdsall R; Chen W
Yakugaku Zasshi; 2017; 137(5):525-528. PubMed ID: 28458283
[TBL] [Abstract][Full Text] [Related]
13. [Development of ADCs Using Molecular Imaging].
Yasunaga M; Manabe S; Tsuji A; Furuta M; Ogata K; Koga Y; Fujiwara Y; Saga T; Matsumura Y
Yakugaku Zasshi; 2017; 137(5):535-544. PubMed ID: 28458285
[TBL] [Abstract][Full Text] [Related]
14. Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.
Spidel JL; Albone EF; Cheng X; Vaessen B; Jacob S; Milinichik AZ; Verdi A; Kline JB; Grasso L
MAbs; 2017; 9(6):907-915. PubMed ID: 28541812
[TBL] [Abstract][Full Text] [Related]
15. Sacituzumab govitecan: an antibody-drug conjugate.
Sahota S; Vahdat LT
Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
[TBL] [Abstract][Full Text] [Related]
16. [Development of New ADC Technology with Topoisomerase I Inhibitor].
Agatsuma T
Yakugaku Zasshi; 2017; 137(5):545-550. PubMed ID: 28458286
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
